12 matches for your search in the start-up spotlight
rss
“Our method, which involves equipping blood cells with a kind of protective shield and then targeting and removing diseased cells, smooths the way for treatments that could not have been used in that way before”
17-Dec-2024
Start-up Cimeio Therapeutics intends to pave the way for gentler and more efficient treatments for diseases such as blood cancer. The company, a spin-off of the University of Basel, has just concluded an important collaboration agreement: Cimeio is joining forces with the pharmaceutical firm ...
University of Basel spin-off Translation-X receives Venture Kick funding
08-Oct-2024
In 2022, Dr. Özgür Genç together with Professor Peter Scheiffele from the Biozentrum, University of Basel, founded the startup Translation-X with the goal of developing novel therapeutics for autism spectrum disorders. They have now received 150’000 Swiss Francs investment from the Venture Kick ...
There is a huge market for the treatment of patients with degenerative brain diseases
15-Apr-2024
The Basel spin-off company Bottneuro is developing a personalized treatment helmet – the Miamind neurostimulator. Thanks to targeted brain electrostimulation, the innovative device is intended to have a positive effect on the course of diseases such as Alzheimer’s, as there is a huge market for ...
New technology uses living bacteria to fight cancer
28-Nov-2023
The biotech company T3 Pharmaceuticals, a spin-off from the University of Basel, is being acquired by the German pharmaceutical company Boehringer Ingelheim. T3 Pharma has developed a novel technology that uses live bacteria to deliver therapeutic proteins to cancer cells and the tumor ...
Repairs within the body: The start-up wants to make blood stem cell transplants easier on the body
04-Jul-2023
Gentler cell therapies for blood cancer and other serious blood diseases – this is the goal that Cimeio Therapeutics, a University of Basel spin-off, has set itself. The start-up has been able to make a great step forward together with a company that offers a pioneering method for the targeted ...
University of Basel and biotech start-up RocketVax present a vaccine concept that could lead to a new generation of vaccines
25-May-2023
Researchers at the University of Basel have developed a new approach for a vaccine against COVID-19. This vaccine is based on a modified coronavirus that can enter body cells and trigger an effective immune response but cannot multiply in the body. In animal studies, the vaccine effectively ...
Development of selective immunosuppressive drugs
05-Jul-2022
NextImmune, a spin-off from the Biozentrum of the University of Basel, has received financial support of 150,000 Swiss francs from the Venture Kick funding initiative. The start-up develops a new generation of immunosuppressive drugs for autoimmune diseases and organ transplantation. The company ...
CHF 46 million for a University of Basel start-up
20-Apr-2022
Cell therapies are the new hope when it comes to tackling diseases such as leukemia or multiple sclerosis, but they require an intensive and strenuous course of pretreatment. Researchers from the University of Basel and the University Hospital of Basel have developed an approach to make both this ...
To date, there is no treatment for this life-threatening genetic disease
02-Mar-2022
Prof. Markus Rüegg and Dr. Judith Reinhard from the Biozentrum of the University of Basel have founded the start-up SEAL Therapeutics AG together with Dr. Thomas Meier, former CEO of Santhera Pharmaceuticals. Their goal is to treat congenital muscular dystrophy using gene therapy and to bring ...
Following refinement with the help of GeneGuide AG, a spin-off from the University of Basel, the app is now available
21-Sep-2021
Researchers from the University of Basel have developed an augmented reality app for smartphones in order to help people reduce their fear of spiders. The app has already shown itself to be effective in a clinical trial, with subjects experiencing less fear of real spiders after completing just a ...
